Brief: Tianda Pharmaceuticals updates on investment in an oncology therapies R&D company
03/12/2015 11:55
Dec 3 (Reuters) - Tianda Pharmaceuticals Ltd 0455.HK : * Voluntary announcement- investment in an oncology therapies research and development company * Deal for total cash consideration of US$3.9 million * Unit Tianda Pharmaceuticals Ltd entered into investment agreement with Aslan Pharmaceuticals Limited and other investors * Under the deal, the unit subscribed for 2.1 million series C convertible preference shares of Aslan * Source text for Eikon ID:nHKS30C8bM ((For more news, please click here 0455.HK )) ((Bengaluru Newsroom; +91 80 6749 1130))
Recent news on Tianda Pharmaceuticals
See all newsBrief: Tianda Pharmaceuticals Says Loss Attributable Expected To Increase To Hk$61 Million For FY
Brief: Tianda Pharmaceuticals Clarifies On Fraudulent Fund Raising Scams
Brief: Tianda Pharmaceuticals Sees Loss Attributable For Interim Period Increase To Not Less Than HK$27 Mln
Brief: Tianda Pharmaceuticals Says Unit Granted Drug Registration Approval Of Ibuprofen Suspension By NMPA
Brief: Tianda Pharmaceuticals Says Drug Registration Approval Of "Nicorandil For Injection" By NMPA